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ABSTRACT
Objective: Malaria is an infection disease caused by Plasmodium parasite with high prevalence in tropic and subtropic countries. The aim of this work 
was to design and screening of gallic acid derivatives as inhibitors of malarial dihydrofolate reductase (DHFR) by in silico docking.
Methods: The derivatives were designed by expanding the carboxyl group of gallic acid with open-chain moiety of L-threonine-allyl esters, as well 
as to modify the hydroxyl groups on the aromatic ring of gallic acid with methoxyl group in the derivatives. In silico approach has been utilized in 
finding the potential antimalaria of gallic acid derivatives. Fourteen gallic acid derivatives (compound 2-15) were modeled into three-dimensional 
(3D) structures by ACD Labs software. Geometry optimization and minimization of energy 3D structure of gallic acid derivatives as ligands using the 
MOE software. Docking process and amino acid analysis were executed using MOE software.
Results: In silico docking study resulted in the three top-ranked compounds, namely, compound 5, 8, and 12. Among those three top-ranked 
compounds, compound 12 (octyl gallate) exhibited the strongest interaction and greatest inhibitory activity against the receptor of malarial DHFR.
Conclusion Our results clearly demonstrated that compound 12 (octyl gallate) could be developed as a promising candidate for the new antimalarial 
agent.
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INTRODUCTION
Malaria is one of the Plasmodium parasite infections which found 
in many tropical and subtropical countries. According to the WHO 
(2010), around 2.3-3.3 billion people suffered in malaria, especially in 
Africa, Asia, Middle East, Latin America, and some parts of Europe [1]. 
Particularly, children under age 5 and pregnant women are people with 
the most severe infection of malaria [2]. In Indonesia, there are 396 
districts of malaria endemic and approximately 45% of the population 
live in areas at risk of malaria [3]. Since 2010, the directorate general 
of disease control and environmental sanitation, Ministry of health, 
Republic of Indonesia, has been used annual parasite incidence (API) to 
express incidence of malaria in Indonesia. Papua, West Papua, and East 
Nusa Tenggara are the provinces with the highest malarial incidence 
with API 18.03, 17.86, and 12.14/1000 population, respectively. 
Strategic Plan of the Ministry of Health Republic of Indonesia in 
2010-2014 targeted to reduce morbidity of malaria from 2 to 1/1000 
population [4,5]. There are four species of the genus Plasmodium 
that can cause infections in humans, namely, Plasmodium falciparum, 
plasmodium vivax, Plasmodium malariae, and Plasmodium ovale. Among 
these four types, the P. falciparum that causes malaria falciparum is the 
most dangerous type because it can cause serious complications which 
lead to the death [6].
Currently, the treatment of malaria caused by P. falciparum parasite 
relies on the use of chloroquine or synergistic combination of 
aminoquinoline-antifolate and sulfadoxine-pyrimethamine. However, a 
recent study reported that antimalarial drugs have shown resistance 
which leads to the decreasing in its effectiveness [7]. This fact indicated 
the new antimalarial drugs that are more potent, more effective, and 
safer are required. Gallic acid (1) is naturally obtained compound 
which showed biological activity as an antioxidant, antifungal, antiviral, 
anti-inflammatory, and anticancer. It has been reported that gallic 
acid significantly inhibited the growth of viruses and bacteria, as well 
as induced apoptosis of cancer cells [8-10]. Previous researchers also 
reported that gallic acid (1) and some of alkyl ester gallate showed 
antimalarial activity. Gallic acid which is one of the main components 
in oregano (Origanum compactum) was reported to have antimalarial 
activity [11]. Researcher from Italy, Sannela et al., reported that gallic 
acid derivatives containing in green tea, namely, epigallocatechin-3-
gallate, and epicatechin gallate showed strong antimalarial activity 
against P. falciparum [12]. In 1999, Murphy and Lang-Unnasch 
reported that the combination of alkyl ester gallate, i.e. propyl gallate 
with atovaquone has antimalarial activity more powerful than the 
combination of atovaquone with gallic acid [13]. This result revealed 
that the alkyl ester derivative of gallic acid (alkyl ester gallate) could 
be developed as an antimalarial drug. The strong antimalarial activity 
of alkyl ester gallate prompted us to carry out research that is aimed 
to design a series of alkyl ester derivative of gallic acid, compound 
2-15 (Fig. 1), as well as to study the interaction of the derivatives 
with receptor target of malarial dihydrofolate reductase (DHFR) by 
computational in silico molecular docking. The three best compounds 
which showed the strongest interaction with receptor target of malarial 
DHFR will be synthesized and will be examined its in vitro and in vivo 
antimalarial activity in our next research project.
Many researchers have been completed the study on the interaction 
of compounds with antimalaria drug targets by in silico molecular 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i2.15712
Research Article
331
Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 330-334
 Arsianti et al. 
docking [14,15]. Sharma and Chetia (2013) conducted docking studies 
on quinine analog for plasmepsin II of malarial parasite [16]. Lulu 
et al. (2015) have been accomplished in silico docking study of 240 
antimalarial compounds with active site of P. falciparum chorismate 
synthase protein [17]. Ravi and Ragunathan (2016) conducted in silico 
analysis of alien and microdontin with P. falciparum calcium-dependent 
protein kinase [18]. In 2014, we conducted in silico molecular docking 
study on antimycin A analogs as inhibitors of antiapoptotic Bcl-2 
of breast cancer [19]. Recently, In 2016, we have reported in silico 
molecular docking studies of opened-chain analogs of antimycin A3 
as caspases inhibitors of apoptosis in colorectal cancer [20]. In this 
work, as a part our continuing research to develop computer-aided 
drug design and screening by docking approach, we conduct in silico 
study and screening of 14 gallic acid derivatives as inhibitors of malarial 
DHFR.
METHODS
Design structure of gallic acid derivatives
A series of gallic acid derivatives were designed by modifying the 
carboxyl group of gallic acid with alkyl ester group which have one 
to eight linear aliphatic carbon chains in derivative 2, 3, 4, 5, 8, 10, 
11, 12, 13, 14, and 15 and have a branched aliphatic carbon chain in 
derivative 6, 7, and 9. The previous studies showed that the methylation 
of the hydroxyl group on the aromatic ring of gallic acid will enhance 
the antiviral activity, so in this study, we modify the hydroxyl groups 
on the aromatic ring of butyl gallate become monomethoxy butyl 
gallate in derivative 13, 3,5-Dihydroxy-4-methoxy benzoic acid butyl 
ester in derivative 14 and trimethoxy butyl gallate in derivative 15. AQ1
These modifications are expected to increase antimalarial activity of 
derivatives 2-15 as growth inhibitors Plasmodium falciparum.
Structure preparation
Gallic acid derivatives were modeled into three-dimensional (3D) 
structures. The modeling is performed using ACD Labs software.
Geometry optimization and energy minimization 3D structure of 
ligands
Geometry optimization and minimization of energy 3D structure of 
gallic acid derivatives (ligands) using the MOE software that runs on 
a single computer Intel Pentium Dual Core. The algorithm used is the 
conjugate gradient Polak–Ribiere with maximum convergence root 
mean square gradient of 0.01 kcal/mol and parameters Å molecular 
mechanics force field MMFFx.
In silico docking of gallic acid derivative on receptor DHFR
The process of in silico docking begins with file preparation using 
a docking program in MOE software. Both molecules of gallic acid 
derivative (then called ligand) and the enzyme, polar hydrogen, and 
Gasteiger charge were added, and nonpolar hydrogen was merged. 
Ligand and enzyme were stored in molecular format file for later use 
in the preparation parameters. Grid box used was 60×60×60 with a 
grid spacing of 0.375 Ǻ. Docking calculations executed by the algorithm 
parameters Lamarckian genetic algorithm with a population size of 
150, 10 million energy evaluation and repetition (engine runs) as much 
as 100 times. These parameters are stored in a format MOE as a file to 
be used to carry out the process of docking. Docking process is executed 
using MOE software.
Fig. 1: Chemical structure of gallic acid (1) and its derivatives (2-15)
332
Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 330-334
 Arsianti et al. 
In silico docking analysis
The results of in silico docking calculations can be seen in output in 
txt format. Determination of heme-ligand conformation results of 
docking is done by selecting ligand conformations which have lowest 
binding affinity energy of the group (cluster) with the largest number 
of population with a limit of a standard deviation of 1.5 Å. Energy 
binding and inhibition constants docking results can be seen in output 
in notepad format. Preferred complex is a complex that has smallest 
binding affinity energy and inhibition constants which subsequently 
used for further analysis. Hydrogen bonding that occurs in complex 
heme-ligand docking best results is identified using MOE software with 
input files in formats.pdb. Contact residue of heme-ligand complex from 
docking results is identified using MOE software.
RESULTS AND DISCUSSION
In silico molecular docking of gallic acid derivatives 
Gallic acid (1) and fourteen derivatives (2-15) were simulated 
using in silico molecular docking on target protein of malarial DHFR 
P. falciparum. The results are displayed in Table 1. The best interaction 
between the compound and the receptor DHFR was assessed based 
on low ∆G binding energy, high pKi affinity, and a number of hydrogen 
acceptor/hydrogen donors (hydrogen bonding interaction) to the 
catalytic site of DHFR target protein.
As shown in Table 1, compared to gallic acid, the derivative compounds 
12, 8, 5, 10,11, 9, 7, and 6 and methoxy butyl gallate 13, 14, and 15, 
exhibited lower ΔG value, indicating that these derivatives have a 
stronger conformational stability against malarial DHFR. Compared to 
butyl gallate (5), derivatives 13, 14, and 15 which have monomethoxy 
group, dimethoxy group, and trimethoxy group on the aromatic ring, 
respectively, showed higher ΔG value and lower pKi value, suggesting 
that replacing the hydroxyl group in 5 with methoxy group in 13, 14, 
and 15 resulted in increasing of stability and affinity against receptor 
DHFR. Furthermore, compared to derivative 6 (isobutyl gallate) and 
derivative 7 (tert butyl gallate) which have branched aliphatic carbon 
chain, derivative 5 (butyl gallate) which has linear aliphatic carbon 
chain, exhibited higher pKi value and stronger hydrogen acceptor/
hydrogen donor interactions. Similar results also observed between 
derivative 8 (amyl gallate) and derivative 9 (isoamyl gallate). Compared 
to derivative 9 which has branched structure, derivative 8 with linear 
structure showed higher stability, higher affinity, and stronger hydrogen 
acceptor/hydrogen donor interactions on receptor malarial DHFR. 
These results revealed that the existence of alkyl ester group with 
linear structure in alkyl ester gallate is more important for antimalarial 
activity compared to alkyl ester group with branched structure. 
Moreover, in silico docking of the derivatives compound 2-12 produced 
the three top-ranked derivatives compounds, namely, derivatives 12 
(octyl gallate), 8 (amyl gallate), and 5 (butyl gallate) as marked in red 
color that showed lower ∆G binding energy value, higher pKi value, 
and a higher number of hydrogen bonding interaction than the others 
compounds. The ∆G values of derivatives 12, 8, and 5 are −12.8806, 
−12.7127, and −9.7506 Kkcal/mol, respectively, which are better than 
gallic acid (1), with a ∆G value of −9.5473 Kcal/mol. These results 
showed that compared to gallic acid, those three top-ranked derivatives 
will form a more stable complex with DHFR as well as be able to inhibit 
and reduce the activity of DHFR better than gallic acid. The pKi value of 
the three top-ranked derivatives is higher than gallic acid, indicating that 
they have a higher affinity and interact effectively with the target DHFR. 
Except the number of hydrogen acceptor/hydrogen donor interactions, 
all of those three top-ranked derivatives have a log P value higher than 
gallic acid (log P: −0.883). Based on Lipinski rule, the hydrophobicity 
properties of drugs or compounds that can penetrate the cell membrane 
is in the range of 1-5. Thus, the log P value of gallic acid <1 indicated 
that gallic acid is hydrophilic and it will be difficult to penetrate the cell 
membrane. Contrast with gallic acid, the three top-ranked compounds 
demonstrated higher hydrophobicity properties in ranging of 1.3-3.3, 
which could penetrate the cell membrane more easily than gallic acid 
and will contribute to strengthen their interaction against receptor 
DHFR.
Ligand complex interaction of three top-ranked derivatives with 
receptor malarial DHFR
Fig. 2 displays the two-dimensional and 3D ligand complex interaction 
of the three top-ranked derivatives 5, 8, and 12 with the receptor target 
malarial DHFR. As shown in Fig. 2, the three best compound derivatives 
12, 8, and 5 were able to enter the target receptor binding sites of DHFR 
and changing its conformation. Thus, derivative 12, 8, and 5 showed 
a strong inhibitory activity against receptor malarial DHFR. Among 
the three top-ranked compound, derivative 12 (octyl gallate) showed 
the highest stability, affinity, the best hydrophobicity properties, and a 
greater inhibitory activity on receptor DHFR. These results indicating 
that the long carbon chain of alkyl ester group (eight carbon chain) in 
gallic acid derivative was necessary to increase its inhibitory activity 
against receptor of malarial DHFR.
CONCLUSION
In conclusion, we have designed and screened 14 gallic acid derivatives 
by in silico docking. The docking study showed derivative 12, that is, 
octyl gallate with eight-long carbon chain of ester group, exhibited 
a greater inhibitory activity against malarial DHFR than gallic acid 
and others derivative. Thus, the derivative 12 (octyl gallate) should 
be considered as a promising candidate for the treatment of malaria 
infection.
ACKNOWLEDGMENTS
We thank to directorate of research and community service (DRPM) 
University of Indonesia, and Directorate for higher education, Ministry 
Table 1: The properties of the derivatives (2-15) and gallic acid (1) on the catalytic site of DHFR
Compound ∆G (Kcal/mol) pKi (µM) Hdon/Hacc  Log P
12 −12.8806 9.824 6  3.321
1 −9.7473 7.808 8 −0.833
5 −9.5506 7.940 6  1.370
3 −9.3146 7.529 5  0.980
8 −12.7127 8.639 5  2.150
4 −12.4858 7.804 4  1.760
10 −11.9845 7.682 3  2.541
2 −8.6675 6.456 3  0.590
13 −11.9899 7.541 4  2.063
11 −11.9253 7.259 2  2.931
9 −11.8890 7.363 3  2.006
15 −10.4856 6.715 2  2.662
14 −10.2458 7.008 3  2.366
7 −10.5877 7.212 2  1.759
6 −10.7084 6.426 1  1.616
DHFR: Dihydrofolate reductase
333
Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 330-334
 Arsianti et al. 
of Research and Technology Republic of Indonesia, for the research 
grant of PUPT (Penelitian Unggulan Perguruan Tinggi, and to the 
Graduate School of Materials Science, Nara Institute of Science and 
Technology (NAIST), Japan for International Research Collaboration 
Program (NAIST Global Initiative Program).
REFERENCES
1. Olumes P. Guidelines for the Treatment of Malaria. 2nd ed. Switzerland: 
WHO; 2011.
2. Croft AM, Jacquerioz FA, Jones KL. Drugs to prevent malaria in 
travellers: A systematic review of randomized controlled trials. Human 
Parasitic Diseases 2010;2:1-19.
3. Margaret C. World Malaria Report. Switzerland: WHO; 2011.
4. Buletin Jendela Data dan Informasi. Epidemiology of Malaria in 
INDONESIA. Volume 1. Triwulan I. Ministry of Health Republic 
of Indonesia, 2011. Available from: http://www.file:///C:/users/user/
downloads/buletin-malaria.pdf.
5. Indonesia National Malaria Control Program Strategic Plan 2015-2019. 




6. Irianto K. Parasitologi Berbagai Penyakit Yang Mempengaruhi 
Kesehatan Manusia. Bandung, Indonesia: Penerbit Yrama Widya; 2009.
7. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, 
et al. Amodiaquine alone, amodiaquine sulfadoxine-pyrimethamine, 
amodiaquine artesunate, and artemether-lumefantrine for outpatient 
treatment of malaria in Tanzanian children: A four-arm randomised 
effectiveness trial. Lancet 2005;365(9469):1474-80.
8. Kaur M, Velmurugan B, Rajamanickam S, Agarwal R, Agarwal C. 
Gallic acid, an active constituent of grape seed extract, exhibits anti-
proliferative, pro-apoptotic and anti-tumorigenic effects against 
prostate carcinoma xenograft growth in nude mice. Pharm Res 
2009;26(9):2133-40.
9. Verma S, Singh A, Mishra A. Gallic acid: Molecular rival of cancer. 
Environ Toxicol Pharmacol 2013;35(3):473-85.
10. You BR, Moon HJ, Han YH, Park WH. Gallic acid inhibits the growth 
of HeLa cervical cancer cells via apoptosis and/or necrosis. Food Chem 
Toxicol 2010;48(5):1334-40.
11. El Babili F, Bouajila J, Souchard JP, Bertrand C, Bellvert F, Fouraste I, 
et al. Oregano: Chemical analysis and evaluation of its antimalarial, 
antioxidant, and cytotoxic activities. J Food Sci 2011;76(3):C512-8.
12. Sannela AR, Messori L, Casini A, Vincieri FF, Bilia AR, Majori G, et al. 
Antimalarial properties of green tea. Biol Pharm Bull 2010;31:903-7.
13. Murphy AD, Lang-Unnasch N. Alternative oxidase inhibitors potentiate 
the activity of atovaquone against Plasmodium falciparum. Antimicrob 
Agents Chemother 1999;43(3):651-4.
14. Kumar TO, Mahadevan KM, Ganapathy PS, Kumara MN. Synthesis 
and molecular docing study of 2 aryl/heteroaryl-6-chloroquinoline-4-









Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 330-334
 Arsianti et al. 
carboxylic acids with plasmodium LDH receptor. Int J Pharm Pharm 
Sci 2014;7(1):431-7.
15. Pradeep PS, Kumar TO, Prashantha N, Mahadevan KM. Synthesis, 
in vitro antibacterial toxicity and molecular docking anticancer activity 
of novel N-[(2-chloroquinolin-3-yl)] methylidene-2-aniline Schiffs 
bases. Int J Curr Pharm Res 2015;7(3):37-46.
16. Sharma P, Chetia D. Docking studies on quinine analog for plasmepsin-II 
of malarial parasite using bioinformatics tool. Int J Pharm Pharm Sci 
2013;5 Suppl 3:681-5.
17. Lulu S, Thabitha A, Priya AM, Vino S. Insignt into the molecular 
interaction of antimalarial compounds as potential chorismate synthase 
inhibitors. Asian J Pharm Clin Res 2015;8(4):45-52.
18. Ravi L, Ragunathan A. Potential drug targets for aloin and microdontin: 
An in silico analysis. Asian J Pharm Clin Res 2016;9(2):194-6.
19. Arsianti A, Fadilah F, Kusmardi K, Tanimoto H, Morimoto T, 
Kakiuchi K. Design and molecular docking study of antimycin A 
analogues as inhibitors of anti-apoptotic Bcl-2 of breast cancer. Open J 
Med Chem 2014;4:79-86.
20. Fadilah F, Arsianti A, Kusmardi K, Tedjo A. Molecular docking 
studies of opened-chain analogues of antimycin A3 as caspases 
inhibitors of apoptosis in colorectal cancer. Asian J Pharm Clin Res 
2016;9(3):350-2.
Author Query???
AQ1: Please check the term.
